Filing Details

Accession Number:
0001735276-24-000022
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-01 16:12:55
Reporting Period:
2024-02-29
Accepted Time:
2024-03-01 16:12:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178670 Alnylam Pharmaceuticals Inc. ALNY Pharmaceutical Preparations (2834) 770602661
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1226295 A Phillip Sharp 675 West Kendall Street
Henri A. Termeer Square
Cambridge MA 02142
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-29 30,000 $59.25 30,000 No 4 M Direct
Common Stock Disposition 2024-02-29 13,005 $150.60 16,995 No 4 S Direct
Common Stock Disposition 2024-02-29 13,557 $151.43 3,438 No 4 S Direct
Common Stock Disposition 2024-02-29 915 $152.40 2,523 No 4 S Direct
Common Stock Disposition 2024-02-29 1,906 $153.62 617 No 4 S Direct
Common Stock Disposition 2024-02-29 101 $154.07 516 No 4 S Direct
Common Stock Disposition 2024-02-29 516 $156.54 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2024-02-29 30,000 $0.00 30,000 $59.25
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2015-06-05 2024-06-04 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 266,899 Indirect by Trust
Footnotes
  1. The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2023. The 30,000 options exercised and sold by the reporting person were due to expire on June 4, 2024.
  2. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $150.00 to $151.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $151.01 to $151.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $152.02 to $152.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.04 to $154.03. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  6. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.06 to $154.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  7. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $156.15 to $156.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  8. Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees.